(Q38056462)

27 August 2017

title

Inhibitors in childhood hemophilia A: genetic and treatment-related risk factors for development and eradication (English)

1 reference

27 August 2017

0 references

0 references

Donna M DiMichele

1

1 reference

27 August 2017

publication date

25 October 2012

1 reference

27 August 2017

published in

Pediatric Blood Cancer

1 reference

27 August 2017

volume

60 Suppl 1

1 reference

27 August 2017

page(s)

S30-3

1 reference

Inhibitor development in haemophilia B: an orphan disease in need of attention

27 August 2017

cites work

1 reference

Assessing risk factors: prevention of inhibitors in haemophilia

21 January 2018

1 reference

Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom

21 January 2018

1 reference

In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study.

21 January 2018

1 reference

Genetic risk factors for inhibitors to factors VIII and IX.

21 January 2018

1 reference

Inhibitors of factor VIII in black patients with hemophilia

21 January 2018

1 reference

Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A.

21 January 2018

1 reference

Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A.

21 January 2018

1 reference

Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A.

21 January 2018

1 reference

Influence of class I and II HLA alleles on inhibitor development in severe haemophilia A patients from the south of Brazil.

21 January 2018

1 reference

Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review

21 January 2018

1 reference

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.

21 January 2018

1 reference

Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A.

21 January 2018

1 reference

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.

21 January 2018

1 reference

Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review

21 January 2018

1 reference

Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers).

21 January 2018

1 reference

21 January 2018

1 reference

21 January 2018

1 reference

Prophylactic treatment effects on inhibitor risk: experience in one centre

21 January 2018

1 reference

Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study

21 January 2018

1 reference

Treatment of haemophilia in the United Kingdom 1981-1996.

21 January 2018

1 reference

21 January 2018

1 reference

Mild haemophilia: a disease with many faces and many unexpected pitfalls

21 January 2018

1 reference

Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A.

21 January 2018

1 reference

Intensive peri-operative use of factor VIII and the Arg593-->Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A.

21 January 2018

1 reference

Factor VIII inhibitors: a 50-year perspective

21 January 2018

1 reference

International workshop on immune tolerance induction: consensus recommendations

21 January 2018

1 reference

Immune tolerance induction in haemophilia: evidence and the way forward

21 January 2018

1 reference

Factor VIII-specific B cell responses in haemophilia A patients with inhibitors.

21 January 2018

1 reference

Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort.

21 January 2018

1 reference

Bortezomib delays the onset of factor VIII inhibitors in experimental hemophilia A, but fails to eliminate established anti-factor VIII IgG-producing cells

21 January 2018

1 reference

Immune tolerance induction with mycophenolate-mofetil in two children with haemophilia B and inhibitor

21 January 2018

1 reference

A shift towards a T cell cytokine deficiency along with an anti-inflammatory/regulatory microenvironment may enable the synthesis of anti-FVIII inhibitors in haemophilia A patients.

21 January 2018

1 reference

IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A.

21 January 2018

1 reference

Gene therapy for immunological tolerance: using 'transgenic' B cells to treat inhibitor formation

21 January 2018

1 reference

Neonatal helper-dependent adenoviral vector gene therapy mediates correction of hemophilia A and tolerance to human factor VIII

21 January 2018

1 reference

Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PBC.24338

1 reference

27 August 2017

1 reference